Special Issue

Drug Delivery across the Blood-Brain Barrier for the Treatment of Brain Diseases

Message from the Guest Editors

This Special Issue focuses on recent advances in the discovery, characterization, translation, and application of drug delivery across the BBB. The aim is to stimulate research interest in this field toward both improving the existing while developing new strategies for efficient drug delivery across BBB, which will be useful for the treatment of brain diseases.

Guest Editors

Dr. Salvatore Valiante

Associate Professor, Department of Biology, University of Naples Federico II, 80126 Naples, Italy

Dr. Annarita Falanga

Department of Agricultural Sciences, University of Naples Federico II, 80055 Portici, Italy

Deadline for manuscript submissions

closed (30 June 2022)



an Open Access Journal by MDPI

Impact Factor 3.9 CiteScore 5.2 Indexed in PubMed



mdpi.com/si/75466

Biomedicines
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

mdpi.com/journal/biomedicines





an Open Access Journal by MDPI

Impact Factor 3.9 CiteScore 5.2 Indexed in PubMed





About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access iournal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to Biomedicines, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

- Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
- 2. Department of Epidemiology, Harvard T.H. Chan School of Public Health. Boston. MA 02115. USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q2 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 15.3 days after submission; acceptance to publication is undertaken in 3.4 days (median values for papers published in this journal in the first half of 2024).